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Glucosidase I is an important enzyme in N-linked glycoprotein processing, removing speciﬁcally distal a-1,2–linked
glucose from the Glc3Man9GlcNAc2 precursor after its en bloc transfer from dolichyl diphosphate to a nascent
polypeptide chain in the endoplasmic reticulum. We have identiﬁed a glucosidase I defect in a neonate with severe
generalized hypotonia and dysmorphic features. The clinical course was progressive and was characterized by the
occurrence of hepatomegaly, hypoventilation, feeding problems, seizures, and fatal outcome at age 74 d. The
accumulation of the tetrasaccharide Glc(a1-2)Glc(a1-3)Glc(a1-3)Man in the patient’s urine indicated a glycosylation
disorder. Enzymological studies on liver tissue and cultured skin ﬁbroblasts revealed a severe glucosidase I deﬁciency.
The residual activity was !3% of that of controls. Glucosidase I activities in cultured skin ﬁbroblasts from both
parents were found to be 50% of those of controls. Tissues from the patient subjected to SDS-PAGE followed by
immunoblotting revealed strongly decreased amounts of glucosidase I protein in the homogenate of the liver, and
a less-severe decrease in cultured skin ﬁbroblasts. Molecular studies showed that the patient was a compound
heterozygote for two missense mutations in the glucosidase I gene: (1) one allele harbored a GrC transition at
nucleotide (nt) 1587, resulting in the substitution of Arg at position 486 by Thr (R486T), and (2) on the other
allele a TrC transition at nt 2085 resulted in the substitution of Phe at position 652 by Leu (F652L). The mother
was heterozygous for the GrC transition, whereas the father was heterozygous for the TrC transition. These base
changes were not seen in 100 control DNA samples. A causal relationship between the a-glucosidase I deﬁciency
and the disease is postulated.
Introduction
Glycoproteins play important roles in many biological
processes. Their N- and/orO-linked carbohydrate chains
are involved in polypeptide folding and stabilizing pro-
tein conformation and can act as targeting signals or as
ligands for cell-surface receptors mediating cell-cell in-
teraction and recognition (Montreuil et al. 1995). The
biosynthesis of N-linked glycans is a complex process,
comprising transfer of a preformed Glc3Man9GlcNAc2
precursor oligosaccharide to the polypeptide and, sub-
sequently, a series of processing reactions catalyzed by
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glycosidases and glycosyltransferases (Montreuil et al.
1996a) (ﬁg. 1).
Inborn errors in the glycan biosynthesis may have
dramatic inﬂuences on the properties and functioning
of the glycoproteins and may lead to severe clinical
syndromes. Defects in the biosynthetic pathway may
occur either in the assembly reactions of the precursor
oligosaccharide or in enzymatic processing. Deﬁcien-
cies of the enzymes involved represent the main causes
of these autosomal recessive diseases (Kornfeld 1998).
Only ﬁve primary disorders due to defective N-gly-
cosylation of glycoproteins have been identiﬁed: (1)
mucolipidosis II (I-cell disease) (MIM 252500) and
mucolipidosis III (MIM 252600) (pseudo-Hurler po-
lydystrophy) (Reitman et al. 1981); (2) leukocyte ad-
hesion deﬁciency, type II (MIM 266265) (Etzioni et al.
1992); (3) congenital dyserythropoietic anemia type II
(HEMPAS disease) (MIM 224100) (Fukada 1990); (4)
paroxysmal nocturnal hemoglobinuria (MIM 311770)
(Rosse 1997); and (5) carbohydrate-deﬁcient glyco-
protein syndrome (CDGS) (MIM 212065, MIM
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Figure 1 Biosynthetic pathway of a di-antennary N-glycan of a glycoprotein. The enzymatic steps are (1) oligosaccharyltransferase transfers
the precursor oligosaccharide from dolichol pyrophosphate (PP-Dol) to the nascent protein; (2) a-glucosidase I removes distal (a1-2)-linked
Glc; (3, 4) a-glucosidase II removes the (a1-3)-linkedGlc residues stepwise; (5) differenta-mannosidases (a-11,2-mannosidase,Man9-mannosidase
and a-mannosidase I) are responsible for the removal of the (a1-2)-linked Man residues; (6) endo-a-1,2-mannosidase removes Glc3Man, creating
the possibility of a detour along the dotted arrow; (7) N-acetylglucosaminyltransferase I adds the ﬁrst GlcNAc residue at a speciﬁc Man residue;
(8) a-mannosidase II removes the two terminal Man residues; (9) N-acetylglucosaminyltransferase II adds a GlcNAc residue to the newly
generated terminal Man residue; (10) b-1,4-galactosyltransferase adds a Gal residue on each GlcNAc residue; (11) a-2,3-sialyltransferase
terminates the glycan with a Neu5Ac residue on each Gal residue.  = glucose (Glc); = mannose (Man); ● = N-acetylglucosamine (GlcNAc);
 = galactose (Gal); T = N-acetylneuraminic acid (Neu5Ac).
601785, MIM 603147, MIM 602616, MIM 154550,
and MIM 601110). Of the latter, several variants have
been described, clinically presenting as multisystem
disorders mainly caused by deﬁciencies of the enzymes
providing sugar donor molecules for the synthesis of
the precursor Glc3Man9GlcNAc2-PP-Dol (Jaeken et al.
1994; Van Schaftingen and Jaeken 1995; de Koning et
al. 1998; Korner et al. 1998, Keir et al. 1999). Genetic
defects in one of the trimming enzymes in the early
part of N-linked oligosaccharide processing, including
glucosidase I, glucosidase II, and various speciﬁc a-
1,2-mannosidases, have hitherto not been observed in
humans or in other higher organisms.
Some inborn diseases related to abnormal glycocon-
jugate metabolism have been diagnosed by the detection
of accumulating unusual carbohydrate-containing ma-
terial in the patient’s urine (Montreuil et al. 1996b).
Many of these products are structurally homologous to
carbohydrate sequences found in the glycans of glyco-
proteins. Their structures provide indirect information
on errors in the biosynthesis. In this report, we describe
the detection and structural analysis of an unknown
oligosaccharide in the urine of a young infant. Together
with morphological, enzymatic, and genetic studies, this
analysis has led to the discovery of a new inborn disease
with fatal outcome, resulting from a severe deﬁciency
of glucosidase I.
Subjects and Methods
Case Report
The proband, born at 36 wk of gestation after an
uneventful pregnancy and delivery, was the ﬁrst child
of consanguineous parents (second cousins). She had a
birth weight of 2,540 g, a length of 48 cm, and a head
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circumference of 33 cm. Marked generalized hypotonia
and hypomotility were noticed, as were dysmorphic fea-
tures, including a prominent occiput, short palpebral
ﬁssures, long eyelashes, broad nose, retrognathia, high
arched palate, generalized edema, and hypoplastic gen-
italia. Her hands were clenched and her ﬁngers over-
lapped, second over third and ﬁfth over fourth. A band
of alopecia was seen on both parietal areas of the skull.
A thoracic scoliosis was present. Gastric tube feeding
was necessary. Hypoventilation and frequent apneas, al-
ready present from birth, evolved to respiratory insuf-
ﬁciency, which required intubation and supportive ven-
tilation at day 28. The proband had a remarkable
intolerance to the administration of ﬂuid and suffered
from lung edema. Her liver became enlarged. Routine
urinanalysis was normal. Urinary organic and amino
acid and serum amino acid proﬁles were normal. Screen-
ing with thin-layer chromatography (TLC) for oligosac-
charides in the urine revealed the predominant presence
of one unidentiﬁed band. Activities of several lysosomal
enzymes were normal in WBC (a-mannosidase, b-ga-
lactosidase, b-glucuronidase, b-hexosaminidase, a-fu-
cosidase, sphingomyelinase). Serum immunoglobulines
were normal, except for IgA, which was undetectably
low. The karyotype was 46, XX. Her blood group was
A rhesus positive. Seizures characterized by rhythmic
clonic jerks of the left arm started at day 21 and later
became more generalized, as they were associated with
rhythmic vertical eye movements and tonic spasms of
the limbs. A suppression-burst pattern was seen on the
EEG. Brain MRI was normal. Electrodiagnostic studies
showed evidence of a demyelinating polyneuropathy
with motor nerve conduction velocities of 10 m/sec in
the lower and 14 m/sec in the upper limbs.Muscle action
potentials had low amplitudes. Visual evoked responses
were ﬂat, as was brain stem response audiometry. Liver,
muscle, and nerve biopsies were performed at day 34.
Septicemia caused by Escherichia coli occurred twice (at
days 17 and 52). Despite maximal supportive therapy,
the patient’s general condition deteriorated. During the
following weeks, her liver became increasingly enlarged,
reaching 7 cm below the ribs. Aspartate aminotransfer-
ase was 80 IU/L (!58), alanine aminotransferase was 34
IU/L (!51), and activated partial thromboplastin time
was 63.4 sec (!37). At age 2 mo, her body weight was
3,350 g, her length was 54 cm, and her head circum-
ference was 36 cm. Seizures occurred more frequently
and the patient lapsed gradually into a stuporous state.
Artiﬁcial ventilation was stopped at day 74. Ten minutes
later the patient expired. Liver and skin specimens were
taken 1 h after death. The brain was removed 1 d later.
Morphological Studies
Muscle biopsy specimens were examined by means of
histoenzymology and electron microscopy (De Cauwer
et al. 1997). Specimens of nerve and skin samples were
examined in semithin sections by light microscopy and
then by electron microscopy. The pathology study of the
central nervous system was done according to described
techniques (Martin 1995). A liver biopsy taken at age
4 wk and a postmortem liver sample were ﬁxed bymeans
of 4% formaldehyde in 0.12 M sodium cacodylate buf-
fer and were studied, as reported elsewhere (Roels et al.
1995).
Isolation and Characterization of the Urinary
Oligosaccharide
Urine from the patient (300 ml) was lyophilized and
the residue dissolved in 15 ml distilled water. The so-
lution was centrifuged and the supernatant applied in
5-ml aliquots to a Bio-Gel P-2 column (68 # 1.6 cm).
The column was eluted with water at a ﬂow rate of 14
ml/h, and the eluate was monitored with a differential
refractometer. Fractions were screened by TLC (Humbel
and Collart 1975), and those containing the orcinol-
positive oligosaccharide, correspondingwith the original
TLC-band, were combined. Puriﬁcation was then done
by high-pH anion-exchange chromatography on a Di-
onex LC system equipped with a CarboPac PA-1 column
(250# 4 mm), by means of a gold electrode and triple-
pulse amperometry for detection. The columnwas eluted
with a linear gradient of 25–115 mM sodium acetate in
0.1 M NaOH for 25 min at a ﬂow rate of 4 ml/min.
Monosaccharide and chemical link analysis were per-
formed as described (Kamerling and Vliegenthart 1989;
Gerwig et al. 1993). Positive-ion matrix-assisted laser
desorption time-of-ﬂight (MALDI-TOF) mass spectra
were recorded with a Voyager-DE (PerSeptive Biosys-
tems) instrument, which was equipped with a VSL-
337ND-N2 laser, operating at an accelerating voltage of
24 kV (grid voltage 92.5%, ion guide wire voltage
0.01%), and which used 2,5-dihydroxybenzoic acid as
a matrix. High-resolution 500-MHz 1H NMR experi-
ments, including two-dimensional total correlation
spectroscopy (TOCSY) and two-dimensional rotating
frame nuclear Overhauser enhancement spectroscopy
(ROESY), were performed on a Bruker AMX-500NMR
spectrometer (Bijvoet Center, Department of Nuclear
Magnetic Resonance Spectroscopy) at 300 K in D2O
(Vliegenthart et al. 1983; Ha˚rd and Vliegenthart 1993).
Enzyme Assays
A skin biopsy was obtained from the patient, from
both her healthy parents, and from age-matched con-
trols. Fibroblast cell cultures were established under
standard conditions. Specimens of liver were obtained
1 h after death, were immediately frozen in liquid ni-
trogen, and were stored at 80C. Control postmortem
liver specimens were obtained from newborn and young
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children who had died of unrelated diseases. One volume
of liver specimen or ﬁbroblast cells was suspended in 9
vol of either buffer A (10 mM sodium phosphate, pH
6.8, containing 0.2% polyoxyethylene 20 cetyl ether, 50
mM phenylmethanesulphonylﬂuoride and 1 mg/ml leu-
peptine) or buffer B (50 mM sodium phosphate, pH 6.5,
containing 1% Thesit, 50 mM phenylmethanesulphon-
ylﬂuoride and 1 mg/ml leupeptine), and then was dis-
rupted by means of a motor-driven glass/teﬂon homog-
enizer. The homogenates were centrifuged at 5,600 #
g for 1 min and the supernatants assayed for glucosidase
I, glucosidase II, Man9-mannosidase and endo-a-1,2-
mannosidase activity. Hydrolysis by glucosidase I and
glucosidase II of ﬂuorescent tetramethylrhodamine
(TMR)-labeled trisaccharideGlc(a1-2)Glc(a1-3)Glc(a1-
O)-(CH2)8COOCH3 and TMR-labeled disaccharide
Glc(a1–3)Glc(a1-O)-(CH2)8COOCH3, respectively, was
measured by incubation of 15 ml of the homogenates
(containing 50–250 mg total protein) in buffer A with 5
ml of a 2-mM solution of the corresponding synthet-
ic substrate in a total volume of 20 ml at 37C (Scaman
et al. 1996). At various time intervals, 0.5-ml samples
were removed and analyzed on silica gel 60 F254 plates,
which were developed in 2-propanol:water:NH4OH
(7:2:1 [v/v/v]). Cleavage products were quantiﬁed di-
rectly on TLC plates by means of a Biometra Biodoc II
system (Westburg) and a LumiAnalyst 3.0 program
(Boehringer).
For measuring glucosidase I and II activities with the
radiolabeled oligosaccharide processing intermediates,
25-ml aliquots of liver or ﬁbroblast cell homogenates
prepared in buffer B (100–200 mg protein) were incu-
bated at 37C with 5 ml of an aqueous stock solution
containing 200 cpm/ml of [14C]Glc3Man9GlcNAc2 or
[14C]Glc2Man9GlcNAc2. At given times, the reactionwas
stopped by the addition of 30 ml acetic acid and the
cleavage products subjected to paper chromatography
by means of 2-propanol:acetic acid:water (29:4:9 [v/v/
v]). Substrate hydrolysis was determined as described
(Bause et al. 1989). The activity of Man9-mannosidase
was assayed under identical conditions with the use of
1,000 cpm of either [14C]labeled Man9GlcNAc2 or
Man5GlcNAc2 as the substrate (Bause et al. 1992). For
the determination of endo-a-1,2-mannosidase activity,
25 ml of the homogenates were incubated with 1,000
cpm of [14C]Glc3Man9GlcNAc2 at 37C, for 24 h and
for 48 h, in the presence of 1 mM EDTA and 2 mM of
the glucosidase I/II inhibitor 1-deoxynojirimycin, in or-
der to prevent nonspeciﬁc substrate degradation (Bause
and Burbach 1996). Samples were chromatographed
with the more polar solvent (2-propanol:acetic acid:
water; 29:8:15 [v/v/v]), to separate [14C]Glc3Man
from uncleaved substrate. [14C]Glc3-1Man9GlcNAc2,
[14C]Man9GlcNAc2 and [
14C]Man5GlcNAc2 were syn-
thesized as described elsewhere (Hettkamp et al. 1982;
Schweden et al. 1986b). Radioactivity was determined
with the use of Bray’s solution as the counting ﬂuid.
SDS-PAGE and Immunoblotting
Liver tissue and ﬁbroblast cells were homogenized in
buffer B and aliquots of the homogenates (50–100 mg
protein) were diluted with 1 vol of 125 mM Tris/HCl,
pH 6.8, containing 4% SDS and 10% 2-mercaptoe-
thanol. The samples were subjected to SDS-PAGE, ac-
cording to Laemmli (1970), followed by electrophoretic
transfer onto nitrocellulose. The protein replica was in-
cubated with rabbit polyclonal antibodies raised against
glucosidase I and glucosidase II, respectively (Bause et
al. 1989; Hentges and Bause 1997). Antigen-antibody
complexes were detected with a goat anti-(rabbit IgG)
antibody-alkaline phosphatase conjugate by staining
with 5-bromo-4-chloro-3-indolyl phosphate and Nitro
Blue tetrazolium chloride. Protein was determined ac-
cording to the Lowry (Lowry et al. 1951) or Bramhall
(Bramhall et al. 1969) procedure, with the use of bovine
serum albumin as a standard.
Molecular Analysis of the Glucosidase I Gene
Total RNA was prepared from the ﬁbroblasts by the
use of Trizol (Life Technology), and ﬁrst-strand cDNA
was synthesized by M-MLV reversed transcriptase (Life
Technology). Genomic DNA was extracted from pe-
ripheral blood leukocytes by the Qiagen-Bloodminiprep
kit (Qiagen) or from the ﬁbroblast cultures by means of
the Easy DNA kit (Invitrogen), according to the man-
ufacturer’s instructions. Oligonucleotide primers were
designed on the basis of the cDNA structure of the glu-
cosidase I gene (HSAGLUCIE, Accession NR. X87237),
to obtain seven overlapping PCR fragments amplifying
the total cDNA sequence. Primer sequences, conditions,
and fragment lengths are given in table 1. The following
numbering system was used: nt 1 is the ﬁrst nt from
exon 1, and the amino acid numbering starts with the
ﬁrst Met residue. The start codon begins at nt 132. The
glucosidase I cDNA sequences from the proband and
both her parents were ampliﬁed in seven overlapping
fragments and were cloned with the use of the TOPO
TA Cloning kit, according to the manufacturer’s instruc-
tions (Invitrogen). Clones were picked, lysed with
NaOH, and ampliﬁed with the use of primers ﬂanking
the insertion point in the vector. These amplimers were
column puriﬁed (Concert Rapid PCR puriﬁcation, Life
Technology) and directly sequenced. For each fragment,
10 different clones were evaluated. Sequencing results
were conﬁrmed on genomic DNA. Both identiﬁed mu-
tations were detectable on the genomic DNA by use of
the same cDNA primers. For the conﬁrmation of the
R486T substitution, the primers Glu1-1395F and Glu1-
1963Rwere used. The resulting amplimers were digested
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Table 1
Oligonucleotide Primers for RT-PCR Ampliﬁcation of the Complete Coding Region
of the Glucosidase I Gene
Primer Pair Primer Sequence
Annealing
Temperature
(C)
Fragment
Size
(bp)
Glu1-3F 5′-CGCTGGCTGGCAGGTGTCGCTAA-3′
Glu1-455R 5′-GGTTTCGGGCTGCGGGTCT-3′ 60 471
Glu1-368F 5′-CTGTGTTGCCTGCCGACTCC-3′
Glu1-880R 5′-TGCCATACTTGGGGGCTGTA-3′ 60 532
Glu1-801F 5′-CAAGGGGCAGTTGAAGTTTA-3′
Glu1-1100R 5′-TGGAATTTTCAGGGTCACCT-3′ 56 319
Glu1-1051F 5′-GAGGACAGAGGTCCAAGTGG-3′
Glu1-1433R 5′-GGAGGGCACTGCTGTAAAAA-3′ 57.5 403
Glu1-1395F 5′-GCAGAAGGTGGACCCAGCCCTCTTT-3′
Glu1-1963R 5′-TGCTCTGCCAGCCGCGTCAG-3′ 62.5 588
Glu1-1900F 5′-CACCCTTCAGTAACCGAGCGGCACC-3′
Glu1-2376R 5′-GCCACACAGCACCCCGCCAGTAG-3′ 62.5 499
Glu1-2306F 5′-CCTTTGGTTTACGCTCCCTT-3′
Glu1-2806R 5′-ATAGACTCTGGATTCACATTCACCC-3′ 56.5 525
Glu1-M2066F 5′-GGGCCCCAGAGCTAGGGGTC-3′
Glu1-2376R As above 59 333
with endonuclease BsmFI, as the base change created an
additional restriction site for this enzyme. For detection
of the base change F652L, a mismatch oligonucleotide
primer Glu1-M2066F was developed, containing a mis-
match at position 4 at the 3′ end of the primer. As
such, a restriction site for the enzyme AvaII is created
in the wild-type sequence and abolished by the base
change. To distinguish the normal from the mutant re-
striction pattern, a double digest was performed with
the endonuclease PstI. Genomic DNA from 100 normal
control samples was ampliﬁed and digested with the re-
spective enzymes.
Results
Morphological Studies
Light microscopy of the liver revealed proliferation
and dilatation of bile ducts enclosed by ﬁbrotic septa
(cholangioﬁbrosis) (ﬁg. 2A). At the periphery of these
ﬁbrotic septa, numerous macrophages were seen. Paren-
chymal cells showed macrovesicular steatosis. Bile
thrombi were seen in the parenchymal cells and in bile
ducts. The lysosomes in the macrophages were enlarged.
In the parenchymal cells, the lysosomes were mostly nor-
mal but numerous. Iron storage was noticed in the mac-
rophages lining the ﬁbrotic septa and in a few paren-
chymal cells. In the 6 wk between biopsy and autopsy,
ﬁbrotic septa, fat accumulation, and iron storage had
clearly increased.
Electron microscopy showed that parenchymal cells
contained numerous inclusions consisting of concentri-
cally arranged lamellae (myelin-like ﬁgures) (ﬁg. 2B).
The lamellae were electron dense and separated from
each other by an electron-lucent equidistant space. The
conﬁguration as a whole enclosed an electron-lucent in-
ner space containing ﬁne granular material. The lamellae
at the periphery of these conﬁgurations often formed
long, irregular extensions into the cytoplasm. Somewere
seen in close proximity to lipid droplets. Similar struc-
tures were found in bile canaliculi, bile duct lumina, and
sinusoids. At these extracellular locations, the ﬁne equi-
distant spacing of the lamellae was less well preserved.
Lamellar conﬁgurations were also found in lysosomes
of macrophages. Apart from the presence of the lamellar
material and widening of the pericanalicular ectoplasm
of the hepatocytes, apparent ultrastructural alterations
were not noticed.
The brain weighed 492 g (normal ). Micro-411 55
scopic examination showed myelination in the corona
radiata, geniculocalcarine tract at the level of the exter-
nal sagittal stratum, corpus callosum, capsula interna,
tracts in the tegmentum of the brain stem and at the
level of the inferior olivary nuclear complex. Myelina-
tion was slightly delayed, but myelination glia was pres-
ent, and morphological evidence of impaired oligoden-
drocyte differentiation was not found. In the upper
cortical layers, small pyramidal cells were ballooned and
did not stain with Sudan III or with PAS. Such ballooning
was found in neurons of all parts of the cortex (ﬁg. 3A);
in pyramidal cells in the Sommer’s ﬁeld of the hippo-
campus; and in some neurons of the reticular formation
of the brain stem, pons, and medulla, such as the nucleus
dorsalis raphae or nucleus pontis centralis oralis. Similar
features were found in the superior olivary nucleus, dor-
sal motor nucleus of the Xth cranial nerve, and in the
lateral cuneate nucleus. Purkinje cells were normal, but
neurons of the dentate nucleus were slightly swollen.
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Figure 2 Morphological aspects of liver tissue from the patient. A, Autopsy liver cryostat section showing proliferation and dilatation of
bile ducts enclosed by ﬁbrotic septa. The parenchymal cells show a glandular rearrangement and contain numerous macroglobular lipid droplets
(Trichrome stain). B, Electron-microscopic image of myelin-like lamellar proﬁle in the cytoplasm of a hepatocyte. The equidistant lamellae form
dense conﬁgurations that are dispersed at their periphery. M = mitochondrion. Original magniﬁcations: A,#250; B,#24,000; scale bar = 0.5
mm.
Some neuronal losses were detected in the lateral parts
of the inferior olivary nucleus.
Electron microscopy revealed large amounts of empty,
membrane-bound vacuoles in neurons of the frontal and
occipital lobes (ﬁg. 3B and C). The vacuoles with di-
ameters varying from 1–1.5 mm were surrounded by a
single membrane and did not contain lamellar or ﬁbrillo-
granular material. Dilated ergastoplasm was found in
the same neurons. On one occasion, a membrane-bound
vacuole containing many small bodies with lamellar pro-
ﬁles was found (“polymorphous cytoplasmic body”).
Light- and electron-microscopic examination of skin and
peripheral nerve revealed no signiﬁcant abnormalities.
Isolation and Identiﬁcation of the Urinary
Oligosaccharide
TLC of the patient’s urine (ﬁg. 4) showed an intense
carbohydrate-positive band not detected in controls.
Figure 3 Morphological aspects of the brain. A, Light-microscopic examination of the cerebral cortex at the level of the gyrus frontalis
superior: swelling of nearly all neuronal perikarya while a small area of cytoplasma around the nucleus remains preserved (formalin ﬁxation,
embedding in parafﬁn, HE-stain, magniﬁcation#350). B, Electron micrograph of a cortical neuron: numerous membrane-bound, empty-looking
vacuoles are present in the neuronal perikaryon. Dilated ergastoplasm is also found. C, At higher magniﬁcation, the limiting membrane of the
empty-looking vacuoles is very easy to distinguish. In the center there is also a dilatation of the endoplasmic reticulum. Fixation in 4% buffered
glutaraldehyde, buffered 2% osmium tetroxide postﬁxation, embedding in araldite, staining with uranyl acetate and lead citrate; scale bar = 1
mm.
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Figure 4 TLC. Lane 1, standard mixture of glucose and lactose;
lane 2, control urine; lane 3, patient’s urine; lane 4, isolated tetrasac-
charide. TLC was performed on Kieselgel 60 F254 plates (0.2 mm;
Merck) with the use of n-butanol:acetic acid:water (2:1:1 [v/v/v])
(Humbel and Collart 1975). Bands were visualized by spraying with
a solution of orcinol/sulfuric acid and heating for 5 min at 130C.
This compound was isolated and puriﬁed by sequential
gel ﬁltration and high-pH anion-exchange chromatog-
raphy. MALDI-TOF spectrometry of the free ([MNa]
at m/z 689) and permethylated ([MNa] at m/z 885)
product indicated a neutral tetrasaccharide Hexose4.
Monosaccharide analysis of the puriﬁed compound re-
vealed the presence of Glc and Man in a molar ratio of
3:1. After reduction with NaBH4, monosaccharide anal-
ysis yielded Glc and mannitol in a molar ratio of 3:1,
showing that Man occupied the reducing end. Chemical
bond analysis, including gas-liquid chromatography/
mass spectrometry of the partially methylated alditol ac-
etates, demonstrated a terminal Glc, a 2- and a 3-sub-
stituted Glc and a 3-substituted Man. The sequence of
the internal Glc residues and the anomeric conﬁgura-
tions of the constituting monosaccharides were estab-
lished by 1H-NMR spectroscopy comprising one-di-
mensional (ﬁg. 5) and two-dimensional (TOCSY and
ROESY) measurements. The structure proved to be the
N-glycan fragment Glc(a1-2)Glc(a1-3)Glc(a1-3)Manof
glycoproteins.
Accumulation of Glc3Man in the Urine Is Caused by
Glucosidase I Deﬁciency
The presence of Glc(a1-2)Glc(a1-3)Glc(a1-3)Man in
the urine of the patient suggested that glucosidase I, the
enzyme cleaving speciﬁcally the distal a1-2-glucose from
the N-linked oligosaccharide precursor, was deﬁcient.
Since Glc3Man9GlcNAc2 is thus not processed in the
endoplasmic reticulum, generation of the Glc3Man
tetrasaccharide must result from endo-a1,2-mannosi-
dase activity in the Golgi. Homogenates from liver tissue
and skin ﬁbroblasts were not able to degrade either
synthetic TMR-labeled Glc(a1-2)Glc(a1-3)Glc(a1-O)-
(CH2)8COOCH3 (ﬁg. 6A and B), or the natural glucos-
idase I substrate [14C]Glc3Man9GlcNAc2 (ﬁg. 6C and D),
supporting the hypothesis that glucosidase I activity was
absent. Residual glucosidase I activity measured with
both substrates was !3% in either cell type. Under iden-
tical conditions, however, the activity of other processing
enzymes, including Man9-mannosidase (Fig. 6C and D),
glucosidase II and endo-a-1,2-mannosidase (data not
shown), was unchanged.
The molecular reason for the glucosidase I deﬁciency
was studied further by analyzing homogenates from liver
tissue and cultured skin ﬁbroblasts by SDS-PAGE, fol-
lowed by immunoblotting, with the use of polyclonal
antibodies raised against glucosidase I and against the
large a-subunit of the glucosidase II complex. Immu-
nostaining of glucosidase I showed strongly decreased
amounts of protein in liver homogenates from the pa-
tient compared to age-matched controls (ﬁg. 7). The im-
munoreaction for glucosidase I from cultured skin ﬁ-
broblasts was positive, although less intense than for
controls. Similar amounts of the glucosidase II a-subunit
were detected immunologically in homogenates from
cells of the patient and of controls. This last observa-
tion excludes the possibility that any differences in im-
munostaining were due to tissue storage or workup
procedures.
In cultured ﬁbroblasts, cells from both parents’ glu-
cosidase I activity, as calculated from initial cleavage
rates, were found to be ∼50% of that for age-matched
controls, whereas activities for Man9-mannosidase (ﬁg.
8) and glucosidase II (data not shown) were normal.
Molecular Analysis of the Glucosidase I Gene
The total glucosidase I cDNA sequence from the pro-
band and both parents were ampliﬁed and sequenced.
The cDNA from the proband disclosed two base
changes: (1) one allele harbored a GrC transition at nt
1587, resulting in the substitution of Arg at position 486
by Thr (R486T), and (2) on the other allele a TrC
transition at nt 2085 resulted in the substitution of Phe
at position 652 by Leu (F652L). The proband and the
mother were found to be heterozygous for the GrC
transition, whereas the proband and the father were
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Figure 5 One-dimensional 500-MHz 1H-NMR spectrum of the urinary tetrasaccharide Glc(a1-2)Glc(a1-3)Glc(a1-3)Man. The spectrum
was recorded in D2O at 300 K. Chemical shifts (d) are expressed in ppm by reference to internal acetone (d 2.225) (Gerwig et al. 1993). f,
noncarbohydrate contaminant. Full assignments of the proton chemical shifts were performed by two-dimensional homonuclear TOCSY (mixing
times, 20 ms and 100 ms) and ROESY (mixing time, 250 ms) experiments. The sequence of the residues followed directly from interresidual
ROE connectivities. The one-dimensional 1H-NMR spectrum is similar to that of the earlier reported 400-MHz spectrum of synthetic Glc(a1-
2)Glc(a1-3)Glc(a1-3)Man (Ogawa et al. 1984), whereas the 1H-NMR data of the Glc residues of the tetrasaccharide were in agreement with
those reported for the Glc residues in the N-glycan Glc3Man9GlcNAc2 (Ronin et al. 1987).
found to be heterozygous for the TrC transition. Am-
pliﬁcation of genomic DNA sequences ﬂanking both al-
terations conﬁrmed the cDNA ﬁndings in the family.
These base changes were not seen in 100 control DNA
samples.
Discussion
The proband presented with abnormal clinical ﬁndings
in the neonatal period, including severe generalized hy-
potonia, dysmorphic features, hypoventilation, feeding
problems, and seizures. An underlying metabolic dis-
order was suspected because of the relentless course of
the disease and the progressive hepatomegaly. Lysosomal
disorders related to N-glycan catabolism were excluded
because the urinary carbohydrate excretion pattern was
different from that reported in patients with lysosomal
exoglycosidases deﬁciencies (Montreuil et al. 1996b). A
peroxisomal disorder was also unlikely because of nor-
mal concentrations of very-long-chain fatty acids, phy-
tanic acid, and plasmalogens in the patient’s serum. The
ﬁnding of a normal IEF pattern of serum sialotransferrin
and of b-trace protein in CSF made the diagnosis of
CDGS unlikely. In the liver, the progressive cholangio-
ﬁbrosis with steatosis and cholestasis was a prominent
ﬁnding (ﬁg. 2A). Furthermore, the concentrically ar-
ranged multilamellar inclusions detected in the cyto-
plasm of parenchymal cells of the patient, not conﬁned
by a lysosomal membrane, were peculiar (ﬁg. 2B). These
phospholipid-like structures were also present in bile
canaliculi and bile duct lumina, which suggests that the
lamellar conﬁgurations represented accumulated bile
components (Phillipps et al. 1993). The fact that the
lamellae were also seen in the sinusoids probably reﬂects
defective bile secretion and regurgitation. In Niemann-
Pick disease, membrane-like structures can also be seen
but are intralysosomal and only detected in parenchymal
cells and Kupffer cells. The inclusions in patients with
CDGS are strictly limited to the lysosomes of parenchy-
mal cells. In our patient, the morphological aspect of
the inclusions was different from these diseases. The ab-
normal intraneuronal vacuoles in the cerebral cortex
were empty probably because their contents were fully
water soluble (ﬁg. 3B). This feature ruled out the di-
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Figure 6 Glucosidase I activity is deﬁcient in the patient. The glucosidase I activity was measured in liver tissue (A and C) and ﬁbroblast
cells (B and D) from the patient (●) and two controls ( and ) by means of a ﬂuorescently labeled (A and B) and a radioactively labeled (C
and D) substrate. The activity of Man9-mannosidase in liver tissue (C) and in ﬁbroblast cells (D) from the patient () and two controls (D and
O) is also shown.
agnosis of any sort of sphingolipidoses and has not been
found by us in a whole range of lysosomal or peroxi-
somal diseases (Ceuterick-de Groote and Martin 1998).
The neuropathological features and especially the ab-
sence of olivopontocerebellar atrophy differ from those
usually described in CDGS (Eyskens et al. 1994).
The enzymatic and immunological data support the
view that a severe deﬁciency of glucosidase I is respon-
sible for the clinical syndrome. Thus, glucosidase I ac-
tivity in cultured skin ﬁbroblasts and liver tissue from
the patient was !3% of those of control values. Fibro-
blasts from the mother and father, on the other hand,
exhibited a phenotype expressing ∼50% of glucosidase
I activity compared to controls, which suggests that
both parents are heterozygous for the enzyme defect.
Immunoblots for liver tissue and cultured skin ﬁbro-
blasts from the patient revealed decreased amounts of
glucosidase I protein in both cell types, although to a
different extent. One explanation for this observation
could be that a catalytically inactive enzyme with nor-
mal molecular mass is synthesized by the patient but is
unstable, being rapidly degraded by proteolysis. We
have, however, no concrete evidence for this proposal,
although increased susceptibility to proteolysis could,
of course, be caused by base substitution in glucosidase
I DNA, resulting in amino acid exchange and possibly
defects in protein folding. This interpretation appears
not unlikely because inactive glucosidase I with normal
molecular mass was identiﬁed immunologically in the
patient’s ﬁbroblasts. Failure to detect inactive enzyme
protein in liver tissue is not necessarily inconsistent with
this interpretation, since proteolysis occursmore rapidly
in liver tissue than in cultured ﬁbroblasts. Another
explanation for the decreased amount of glucosidase I
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Figure 7 Immunoblots by means of polyclonal antibodies
against glucosidase I (GI) and glucosidase II (GII) in liver tissue and
ﬁbroblast cells from the patient (P) and controls (C). In liver tissue
from the patient, the amount of cross-reactive material (CRM) for
glucosidase I is undetectably low, and that for glucosidase II is normal.
In ﬁbroblast cells, the amount of CRM for glucosidase I is signiﬁcantly
lower in the patient than in controls, and that for glucosidase II is
normal.
Figure 8 The initial rate of glucosidase I activity (ﬁrst 30 min)
in both the father and the mother is ∼50% of that in controls. Glu-
cosidase I activity was assayed with a radioactive-labeled substrate in
ﬁbroblast cells from the patient’s father (●) and mother () and from
two controls ( and ). The activities of Man9-mannosidase in the
cells from the father () and the mother (D) are comparable to those
in the control (O).
protein in the patient could be a defect in glucosi-
dase I expression, although this is unlikely given the
known effects of exchanging a single base on mRNA
degradation.
The excessive excretion of Glc3Man in the patient’s
urine has been the initial ﬁnding that has led to the
diagnosis of the glucosidase I deﬁciency. Removal of the
distal (a1-2)-linked glucose residue from the N-linked
Glc3Man9GlcNAc2 precursor by glucosidase I is a highly
speciﬁc processing step that cannot be performed by
other a-glucosidases such as glucosidase II or lysosomal
acid maltase. The severe glucosidase I deﬁciency pre-
cludes further processing steps involving glucosidase II
and the various other a-mannosidases. As a conse-
quence, the formation of complex type N-linked glycans
is signiﬁcantly impaired. The patient’s survival for 2 mo
may point to the existence of an alternate pathway al-
ready sufﬁciently functional to overcome, at least in
part, the glucosidase I deﬁciency (ﬁg. 1). Endo-a-1,2-
mannosidase that is located in the Golgi cleaves N-
linked Glc3-1Man9GlcNAc2 oligosaccharides to yield
Glc3-1Man units (Lubas and Spiro 1988). Glucosidase
II-deﬁcient PHAR2.7 mutant mouse lymphoma cells and
HepG2 cells grown in the presence of glucosidase in-
hibitors were found to use this endoenzyme as a bypass
mechanism for N-linked oligosaccharide processing
(Moore and Spiro 1990; Fujimoto and Kornfeld 1991).
The glucosidase I deﬁciency hypothesis was supported
by the observation that endo-a-D-mannosidase activity
was present in cultured skin ﬁbroblasts from the patient
at comparable levels to those of controls.
Glucosidase I has been puriﬁed from various sources
(Hettkamp et al. 1984; Bause et al. 1989; Schweden et
al. 1986a; Schailubhai et al. 1987). The sequence of the
full-length human glucosidase I cDNA contains 2881
bp and encodes a polypeptide of 834 amino acids cor-
responding to a protein with a molecular mass of ∼92
kDa (Kalz-Fu¨ller et al. 1995). The gene for glucosidase
I is located on chromosome 2 (p12-p13) (Kalz-Fu¨ller et
al. 1996). Molecular analysis performed on cDNA iso-
lated from ﬁbroblast strains showed that, parental con-
sanguinity notwithstanding, the patient was a com-
pound heterozygote, since two base changes, resulting
at position 486 in the substitution of Arg by Thr and
at position 652 in the substitution of Phe by Leu, have
been observed. The former mutation was found in the
mother only, whereas the latter mutation was found in
the father only.
In neonates with rapidly progressive neurodegener-
ative disease, the assay of oligosaccharides in the urine
is a worthwhile test. This disorder of glycoprotein, met-
abolically allied to the oligosaccharidoses, represents a
new entity among them but is surprisingly more rapidly
progressive. Because its clinical phenotype is rather
aspeciﬁc, its prevalence may be underestimated. The
compound heterozygous genotype of the patient tends
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to support this notion. More observations must be ob-
tained before phenotype and pathogenesis will be better
deﬁned.
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